COYA 101
Alternative Names: ALS-001; COYA-101Latest Information Update: 31 Mar 2023
At a glance
- Originator Coya Therapeutics
- Class T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Yes - Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
Most Recent Events
- 29 Mar 2023 COYA 101 is available for licensing as of 29 Mar 2023. www.coyatherapeutics.com 9385166
- 01 Sep 2022 Efficacy, adverse event and pharmacodynamics data from an open-label extension (OLE) of phase IIa trial in Amyotrophic lateral sclerosis released by Coya Therapeutics
- 10 Jun 2022 Coya Therapeutics plans a phase IIb trial for Amyotrophic lateral sclerosis in 2024 (Coya Therapeutics Pipeline, October 2022)